Anti-chymase aptamer and use for same

Abstract

The present invention provides an aptamer that binds to chymase, and contains a common sequence represented by UAACR 1 N 1 R 2 GGGG wherein R 1 and R 2 are each any one base, and N 1 shows 3 to 30 bases (uracil is optionally thymine).

1 . An aptamer that binds to chymase, and comprises a potential secondary structure represented by the formula (1), wherein uracil is optionally thymine:
                       wherein                         in the formula (1) is a stem-loop partial structure, and R   1  and R 2  are each any one base,
 wherein a base length of the aptamer is not less than 28, the stem-loop partial structure of (1′) has a base length of 3 21, and at least two bases at the 5′ end of the UAAC sequence and at least two bases at the 3′ end of the GGGG sequence form base pairs, and 
 wherein the aptamer comprises a nucleotide sequence selected from any of SEQ ID NOs: 1-11, 14-33, and 42-84, wherein uracil is optionally thymine, and wherein one to several nucleotides are substituted, deleted, inserted or added in the nucleotide sequence other than the sequence UAAC and GGGG in the formula (1). 
 
     
     
         2 . The aptamer according to  claim 1 , wherein a hydroxyl group at the 2′-position of ribose of each pyrimidine nucleotide contained in the aptamer is the same or different and unsubstituted or substituted by an atom or a group selected from the group consisting of a hydrogen atom, a fluorine atom and a methoxy group. 
     
     
         3 . The aptamer according to  claim 1 , wherein a hydroxyl group at the 2′-position of ribose of each purine nucleotide contained in the aptamer is the same or different and unsubstituted or substituted by an atom or a group selected from the group consisting of a hydrogen atom, a fluorine atom and a methoxy group. 
     
     
         4 . A complex comprising the aptamer and the functional substance according to  claim 1 . 
     
     
         5 . A medicament comprising the aptamer according to  claim 1 . 
     
     
         6 . The medicament according to  claim 5  that is a therapeutic drug for a disease involving organ or tissue fibrosis, or a circulatory disease. 
     
     
         7 . The medicament according to  claim 5  that is a therapeutic drug for fibrosis. 
     
     
         8 . A method for detecting chymase, comprising using the aptamer according to  claim 1 .